Monoclonal antibodies as effective therapeutic agents for solid tumors
Authors:
Open Access
- 31 August 2004
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 95 (8) , 621-625
Abstract
Monoclonal antibodies (mAbs) against growth factors or their receptors have been revealed to be effective therapeutic agents for solid tumors. Trastuzumab (humanized anti‐HER2 mAb) is the first mAb approved for the treatment of a solid tumor, metastatic breast cancer. Large‐scale phase III clinical trials are now ongoing to further evaluate the additive effects on chemotherapy and the efficacy as a maintenance monotherapy. Another anti‐HER2 mAb CH401 that we developed also seems to have good potential. This chimeric mAb completely suppressed the growth of established human tumor xenografts in SCID mice after a single injection. Furthermore, CH401 characteristically showed much stronger induction of apoptosis in HER2‐overexpressing gastric cancer cells compared to trastuzumab. Additional targets now being intensively evaluated are epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). Both cetuximab (chimeric anti‐EGFR mAb) and bevacizumab (humanized anti‐VEGF mAb) have recently been shown to be of clinical value for metastatic colorectal cancer. Anti‐idiotype mAbs are unique as active immunotherapeutic agents, and survival benefits have been observed in clinical trials for solid tumors.Keywords
This publication has 37 references indexed in Scilit:
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004
- Clinical Cardiac Tolerability of TrastuzumabJournal of Clinical Oncology, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerBritish Journal of Cancer, 2003
- Ongoing adjuvant trials with trastuzumab in breast cancerSeminars in Oncology, 2003
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCritical Reviews in Oncology/Hematology, 2001
- Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancerBritish Journal of Cancer, 1996
- Significance of erb B‐2 Gene Product as a Target Molecule for Cancer TherapyScandinavian Journal of Immunology, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975